A Phase II Study of Neoadjuvant Cisplatin and Gemcitabine Plus Sorafenib for Patients With Transitional-Cell Carcinoma of the Bladder.

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Oct 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Sep 2017 Results of a genomic analysis presented at the 42nd European Society for Medical Oncology Congress.
06 Jun 2017 Results assessing molecular features underlying response to neoadjuvant gemcitabine, cisplatin, and sorafenib in muscle-invasive urothelial bladder carcinoma patients, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
16 May 2017 Results presented at the 112th Annual Meeting of the American Urological Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com